COMP <GO>
BLLN vs MRK // PIOTROSKI F-SCORE QUALITY
BillionToOne Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BLLN 5
— MRK 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: BLLN
LAST: $113.32 (-1.32%) • MKT CAP: $5.42B
piotroski-score
9/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BLLN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BLLN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 74.80% | -6.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.90% | 20.70% | -17.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 0.29% | 3.42% | -3.13 | MRK | /fcf-yield <GO> |
| Operating Margin | 5.30% | 34.30% | -29.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 28.10% | -25.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 100.00% | 1.30% | +98.70 | BLLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.24 | 5.19 | +17.05 | BLLN | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 7/9 | +2.00 | BLLN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.5 | 56.9 | +2.62 | BLLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.92 | +0.10 | BLLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 18.4x | +121.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $361.02B | -$355.60B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BLLN REV | MRK REV | BLLN GROSS % | MRK GROSS % | BLLN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $305.1M | $65.01B | 68.3% | 74.8% | $15.7M | $12.36B |
| FY 2024 | $152.6M | $64.17B | 53.0% | 76.3% | -$46.8M | $18.10B |
| FY 2023 | $71.7M | $60.12B | 44.0% | 44.0% | -$56.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BLLN // BETA 1.02
MRK // BETA 0.92